SHC on Nasdaq
Sotera Health Co
We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry.4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Progyny, Inc., Tivity Health or VIEMED HEALTHCARE, INC., or pick any stock.
- TickerSHC on Nasdaq2
- IndustryServices-Misc Health & Allied Services, NEC2
- HeadquartersWilmington, United States2
- Incorporated inDE3
- Business address9100 South Hills Blvd, Suite 300, Broadview Heights, Oh 441473
- Filer categoryLarge accelerated filer3
- Legal formLimited Liability Company2
- LEI549300OVT7MBXFLOFU202
- StatusActive2
- LEI statusIssued and current2
- Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 57124062
See how the biggest companies compare on our leaderboards
We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health ® . We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. In 2025, our customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers’ manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of our services are necessary for our customers to satisfy …4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
55.5%Gross margin5
6.7%Net margin5
5.7%Revenue growth, 20255
12.9%Return on equity5
3.51×Debt to equity5
$149.2MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Service brought in 86% of the revenue Sotera Health Co broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Service | $905.6M | $941.8M | $995.8M |
| Product | $143.7M | $158.6M | $167.9M |
Business segments
Sterigenics brought in 65% of the revenue Sotera Health Co broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Sterigenics | $667.1M | $697.9M | $755.8M |
| Nelson Labs | $221.7M | $229.2M | $220.2M |
| Nordion | $160.5M | $173.4M | $187.6M |
Regions
United States brought in 54% of the revenue Sotera Health Co broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $591.0M | $616.7M | $629.5M |
| Europe | $187.5M | $196.0M | $232.2M |
| Canada | $192.1M | $208.9M | $221.9M |
| Other Geographical Areas | $78.7M | $78.9M | $79.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue45¢$518.1M
- Selling, general and admin22¢$252.8M
- Other costs21¢$245.3M
- Income tax6¢$69.6M
- Profit7¢$77.9M
Out of $1.2B in revenue.5
Where each dollar of operating cash went, fiscal 2025
- Capital spending48¢$138.0M
- Kept or used elsewhere52¢$149.2M
Out of $287.2M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total net revenues | $1.2B | $1.1B | $1.0B |
| Total cost of revenues | $518.1M | $498.1M | $472.1M |
| Gross profit | $645.5M | $602.3M | $577.2M |
| Selling, general and administrative expenses | $252.8M | $242.6M | $236.7M |
| Amortization of intangible assets | $30.7M | $62.0M | $63.8M |
| Interest expense, net | $155.7M | $164.7M | $142.9M |
| Loss on refinancing of debt | $1.5M | $24.2M | $0 |
| Foreign exchange loss | $947.0K | $199.0K | $159.0K |
| Other income, net | -$8.5M | -$5.3M | -$7.4M |
| Income before income taxes | $147.5M | $113.9M | $106.0M |
| Provision for income taxes | $69.6M | $69.5M | $54.7M |
| Net income | $77.9M | $44.4M | $51.4M |
| Pension and post-retirement benefits (net of taxes of $600, $2,804 and $(3,420), respectively) | $2.4M | $8.5M | -$10.5M |
| Interest rate derivatives (net of taxes of $(718), $(1,856) and $(5,467), respectively) | -$2.1M | -$5.4M | -$15.7M |
| Foreign currency translation | $98.1M | -$118.6M | $40.2M |
| Comprehensive income (loss) | $176.4M | -$71.2M | $65.3M |
| Basic (in dollars per share) | $0.27 | $0.16 | $0.18 |
| Diluted (in dollars per share) | $0.27 | $0.16 | $0.18 |
| Basic (in shares) | 284.0M shares | 282.8M shares | 281.0M shares |
| Diluted (in shares) | 286.4M shares | 284.9M shares | 283.2M shares |
| Pension and post-retirement benefits, tax | $600.0K | $2.8M | -$3.4M |
| Interest rate swaps, tax | -$718.0K | -$1.9M | -$5.5M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $344.6M | $277.2M | |||
| Restricted cash short-term | $1.8M | $1.6M | |||
| Accounts receivable, net of allowance for uncollectible accounts of $2,968 and $2,532 as of December 31, 2025 and 2024, respectively | $139.3M | $140.3M | |||
| Inventories, net | $54.4M | $49.2M | |||
| Prepaid expenses and other current assets | $65.2M | $51.0M | |||
| Income taxes receivable | $8.0M | $6.7M | |||
| Total current assets | $613.4M | $526.0M | |||
| Property, plant, and equipment, net | $1.1B | $1.0B | |||
| Operating lease assets | $33.4M | $27.6M | |||
| Deferred income taxes | $3.9M | $2.9M | |||
| Post-retirement assets | $53.8M | $42.5M | |||
| Other assets | $36.7M | $37.1M | |||
| Other intangible assets, net | $288.2M | $317.7M | |||
| Goodwill | $1.1B | $1.1B | $1.1B | ||
| Total assets | $3.3B | $3.1B | |||
| Accounts payable | $78.0M | $55.1M | |||
| Accrued liabilities | $124.7M | $90.5M | |||
| Deferred revenue | $18.0M | $15.1M | |||
| Current portion of long-term debt | $14.0M | $14.8M | |||
| Current portion of finance lease obligations | $3.5M | $2.9M | |||
| Current portion of operating lease obligations | $5.8M | $5.1M | |||
| Income taxes payable | $5.7M | $7.6M | |||
| Total current liabilities | $249.6M | $191.0M | |||
| Long-term debt | $2.1B | $2.2B | |||
| Finance lease obligations, less current portion | $93.8M | $95.3M | |||
| Operating lease obligations, less current portion | $29.9M | $24.5M | |||
| Noncurrent asset retirement obligations | $53.5M | $49.3M | |||
| Deferred lease income | $17.1M | $16.8M | |||
| Post-retirement obligations | $8.1M | $7.9M | |||
| Noncurrent liabilities | $7.4M | $4.4M | |||
| Deferred income taxes | $71.1M | $69.5M | |||
| Total liabilities | $2.7B | $2.7B | |||
| Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at December 31, 2025 and 2024 | $2.9M | $2.9M | |||
| Preferred stock, with $0.01 par value, 120,000 shares authorized; no shares issued at December 31, 2025 and 2024 | $0 | $0 | |||
| Treasury stock, at cost (1,666 and 2,571 shares at December 31, 2025 and 2024, respectively) | -$17.0M | -$23.4M | |||
| Additional paid-in capital | $1.3B | $1.2B | |||
| Retained deficit | -$532.1M | -$610.0M | |||
| Accumulated other comprehensive loss | -$109.8M | -$208.3M | |||
| Total equity | $606.0M | $404.9M | $443.7M | $350.2M | |
| Total liabilities and equity | $3.3B | $3.1B | |||
| Allowance for uncollectible accounts | $3.0M | $2.5M | |||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |||
| Common stock, shares authorized (in shares) | 1.2B shares | 1.2B shares | |||
| Common stock, shares issued (in shares) | 286.0M shares | 286.0M shares | |||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | |||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |||
| Treasury stock (in shares) | 1.7M shares | 2.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2020-12-31 | 2020-11-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $344.6M | $277.2M | ||||
| Restricted cash short-term | $1.8M | $1.6M | ||||
| Accounts receivable, net of allowance for uncollectible accounts of $2,968 and $2,532 as of December 31, 2025 and 2024, respectively | $139.3M | $140.3M | ||||
| Inventories, net | $54.4M | $49.2M | ||||
| Prepaid expenses and other current assets | $65.2M | $51.0M | ||||
| Income taxes receivable | $8.0M | $6.7M | ||||
| Total current assets | $613.4M | $526.0M | ||||
| Property, plant, and equipment, net | $1.1B | $1.0B | ||||
| Operating lease assets | $33.4M | $27.6M | ||||
| Deferred income taxes | $3.9M | $2.9M | ||||
| Post-retirement assets | $53.8M | $42.5M | ||||
| Other assets | $36.7M | $37.1M | ||||
| Other intangible assets, net | $288.2M | $317.7M | ||||
| Goodwill | $1.1B | $1.1B | $1.1B | |||
| Total assets | $3.3B | $3.1B | ||||
| Accounts payable | $78.0M | $55.1M | ||||
| Accrued liabilities | $124.7M | $90.5M | ||||
| Deferred revenue | $18.0M | $15.1M | ||||
| Current portion of long-term debt | $14.0M | $14.8M | ||||
| Current portion of finance lease obligations | $3.5M | $2.9M | ||||
| Current portion of operating lease obligations | $5.8M | $5.1M | ||||
| Income taxes payable | $5.7M | $7.6M | ||||
| Total current liabilities | $249.6M | $191.0M | ||||
| Long-term debt | $2.1B | $2.2B | ||||
| Finance lease obligations, less current portion | $93.8M | $95.3M | ||||
| Operating lease obligations, less current portion | $29.9M | $24.5M | ||||
| Noncurrent asset retirement obligations | $53.5M | $49.3M | ||||
| Deferred lease income | $17.1M | $16.8M | ||||
| Post-retirement obligations | $8.1M | $7.9M | ||||
| Noncurrent liabilities | $7.4M | $4.4M | ||||
| Deferred income taxes | $71.1M | $69.5M | ||||
| Total liabilities | $2.7B | $2.7B | ||||
| Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at December 31, 2025 and 2024 | $2.9M | $2.9M | ||||
| Preferred stock, with $0.01 par value, 120,000 shares authorized; no shares issued at December 31, 2025 and 2024 | $0 | $0 | ||||
| Treasury stock, at cost (1,666 and 2,571 shares at December 31, 2025 and 2024, respectively) | -$17.0M | -$23.4M | ||||
| Additional paid-in capital | $1.3B | $1.2B | ||||
| Retained deficit | -$532.1M | -$610.0M | ||||
| Accumulated other comprehensive loss | -$109.8M | -$208.3M | ||||
| Total equity | $606.0M | $404.9M | $443.7M | $350.2M | ||
| Total liabilities and equity | $3.3B | $3.1B | ||||
| Allowance for uncollectible accounts | $3.0M | $2.5M | ||||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | $0.01 | |||
| Common stock, shares authorized (in shares) | 1.2B shares | 1.2B shares | 1.2B shares | |||
| Common stock, shares issued (in shares) | 286.0M shares | 286.0M shares | ||||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | $0.01 | |||
| Preferred stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | 120.0M shares | |||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||||
| Treasury stock (in shares) | 1.7M shares | 2.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $77.9M | $44.4M | $51.4M |
| Depreciation | $94.9M | $84.3M | $76.6M |
| Amortization of intangible assets | $41.8M | $79.4M | $81.3M |
| Loss on refinancing of debt | $1.5M | $24.2M | $0 |
| Deferred income taxes | $22.0K | $9.4M | $3.4M |
| Share-based compensation expense | $30.9M | $36.8M | $32.2M |
| Accretion expense | $2.3M | $2.6M | $2.4M |
| Unrealized foreign exchange loss (gain) | $9.5M | -$18.3M | $6.1M |
| Unrealized (gain) loss on derivatives not designated as hedging instruments | -$863.0K | $2.2M | -$1.6M |
| Amortization of debt issuance costs | $5.4M | $7.2M | $9.1M |
| Other | -$4.3M | -$5.4M | -$5.3M |
| Accounts receivable | $7.2M | $2.2M | -$21.7M |
| Inventories | -$2.4M | -$4.8M | -$10.0M |
| Other current assets | -$12.9M | $3.6M | $4.0M |
| Accounts payable | $5.2M | -$6.6M | -$5.3M |
| Accrued liabilities | $1.9M | $7.1M | $3.5M |
| Income taxes payable / receivable, net | -$5.5M | $1.5M | $924.0K |
| Other liabilities | $295.0K | -$3.8M | -$1.7M |
| Other long-term assets | $212.0K | -$6.8M | -$238.0K |
| Net cash provided by (used in) operating activities | $287.2M | $224.2M | -$147.7M |
| Purchases of property, plant and equipment | -$138.0M | -$179.1M | -$215.0M |
| Other investing activities | $2.9M | $74.0K | $69.0K |
| Net cash used in investing activities | -$135.1M | -$179.0M | -$214.9M |
| Proceeds from long-term borrowings | $0 | $2.3B | $500.0M |
| Payment of revolving credit facility | $0 | $0 | -$200.0M |
| Payments of debt issuance costs and debt discount | -$4.4M | -$32.1M | -$25.6M |
| Payments of long-term borrowings | -$86.1M | -$2.3B | -$2.5M |
| Buyout of leased facility | $0 | -$6.7M | $0 |
| Shares withheld for employee taxes on equity awards | -$6.6M | -$4.4M | -$4.1M |
| Other financing activities | -$3.5M | -$2.3M | -$1.8M |
| Net cash (used in) provided by financing activities | -$100.5M | -$50.6M | $266.0M |
| Effect of exchange rate changes on cash and cash equivalents | $16.1M | -$17.4M | $2.0M |
| Net increase (decrease) in cash and cash equivalents, including restricted cash | $67.6M | -$22.8M | -$94.6M |
| Cash paid during the period for interest | $164.0M | $179.9M | $173.8M |
| Cash paid during the period for income taxes, net of tax refunds received | $60.9M | $65.8M | $50.2M |
| Purchases of property, plant and equipment included in accounts payable | $25.3M | $10.2M | $16.7M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Sotera Health Co, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerAlton Shader May 27, 2026 to now12
- Chief executive officerMichael B. Petras Jr. Nov 20, 2020 to May 27, 202613
- ChairMichael B. Petras Jr. Nov 20, 2020 to now13
- PresidentMichael P. Rutz Nov 20, 2020 to now14
- Chief financial officerJonathan M. Lyons Jul 6, 2023 to now15
- Chief financial officerMichael F. Biehl Jul 26, 2022 to Jul 26, 202216
- Chief financial officerScott J. Leffler Nov 20, 2020 to Mar 4, 202217
Board members and other officers (20)
- Former SVP, GC and Sec.Alexander Dimitrief Apr 2, 2026 to now18
- SVP, GC and SecretaryTerry Hammons Nov 5, 2021 to Mar 4, 202219
- SVP, GC and SecretaryMatthew J. Klaben Nov 20, 2020 to Oct 7, 202220
- Board memberRichard G. Kyle Feb 13, 2026 to now21
- Board memberKenneth D. Krause Mar 20, 2026 to now22
- Board memberAlton Shader May 27, 2026 to now12
- Board memberHoldco L.p. Bull Mar 6, 2024 to now23
- Board memberChristopher Simon Aug 9, 2024 to now24
- Board memberKaren Flynn Nov 21, 2023 to now25
- Board memberRobert Brown Knauss Oct 24, 2022 to now26
- Board memberDavid E. Wheadon May 28, 2021 to now27
- Board memberAnn R. Klee Nov 20, 2020 to now28
- Board memberConstantine S. Mihas Nov 20, 2020 to now29
- Board memberDavid Donnini Nov 20, 2020 to May 29, 202430
- Board memberJames Neary Nov 20, 2020 to now31
- Board memberRuoxi Chen Nov 20, 2020 to now32
- Board memberSean Laurence Cunningham Nov 20, 2020 to now33
- Board memberStephanie Geveda Nov 20, 2020 to May 31, 202234
- Board memberVincent K. Petrella Nov 20, 2020 to now35
- General counselAlexander Dimitrief Nov 8, 2022 to now36
Former names
- Sotera Health Topco, Inc.Sep 2, 2020 to Oct 9, 20203
Timeline
Filings
285 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 67 major events, 126 insider forms, 29 large holders, 43 other. The latest 20:
- Oct 9, 2026SCHEDULE 13G/A EDGAR
- Aug 19, 20264 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 14, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 11, 20264 EDGAR
- Aug 7, 2026144 EDGAR
- Aug 7, 20264 EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 30, 2026SCHEDULE 13G/A EDGAR
- May 29, 2026SD EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20263 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
The 285 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
28 open-market trades by officers, directors and large owners since October 2021: 0 buys and 28 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Petras Michael B. Jr.Executive Chairman | Sale | 1,144,515 | $18.50 | $21.2M | Form 4 |
| Aug 7, 2026 | Rutz Michael PPresident of Sterigenics | Sale | 150,000 | $18.84 | $2.8M | Form 4 |
| May 13, 2026 | Warburg Pincus (Cayman) XI, L.P.Director | Sale | 19,102,952 | $15.17 | $289.8M | Form 4 |
| May 13, 2026 | Warburg Pincus XI, L.P.Director | Sale | 19,102,952 | $15.17 | $289.8M | Form 4 |
| May 13, 2026 | GTCR FUND XI/C LPDirector | Sale | 12,735,301 | $15.17 | $193.2M | Form 4 |
| Mar 6, 2026 | Warburg Pincus Partners GP LLCDirector | Sale | 15,000,000 | $15.27 | $229.1M | Form 4 |
| Mar 6, 2026 | Warburg Pincus Partners II, L.P.Director | Sale | 15,000,000 | $15.27 | $229.1M | Form 4 |
| Mar 6, 2026 | GTCR CO-INVEST XI LPDirector | Sale | 10,000,000 | $15.27 | $152.7M | Form 4 |
| Dec 8, 2025 | Petras Michael B. Jr.Executive Chairman | Sale | 750,000 | $16.45 | $12.3M | Form 4 |
| Dec 3, 2025 | WARBURG PINCUS LLCDirector | Sale | 9,720,000 | $16.33 | $158.7M | Form 4 |
| Dec 3, 2025 | Warburg Pincus Partners GP LLCDirector | Sale | 9,720,000 | $16.33 | $158.7M | Form 4 |
| Dec 3, 2025 | GTCR FUND XI/A LPDirector | Sale | 6,480,000 | $16.33 | $105.8M | Form 4 |
| Nov 10, 2025 | Warburg Pincus Private Equity XI-C, L.P.Director | Sale | 18,000,000 | $15.65 | $281.7M | Form 4 |
| Nov 10, 2025 | Warburg Pincus Partners II, L.P.Director | Sale | 18,000,000 | $15.65 | $281.7M | Form 4 |
| Nov 10, 2025 | GTCR FUND XI/A LPDirector | Sale | 12,000,000 | $15.65 | $187.8M | Form 4 |
| Sep 5, 2025 | Warburg Pincus XI-C, LLCDirector | Sale | 12,000,000 | $15.11 | $181.3M | Form 4 |
| Sep 5, 2025 | WARBURG PINCUS & CO.Director | Sale | 12,000,000 | $15.11 | $181.3M | Form 4 |
| Sep 5, 2025 | GTCR INVESTMENT XI LLCDirector | Sale | 8,000,000 | $15.11 | $120.9M | Form 4 |
| Aug 22, 2025 | Rutz Michael PPresident of Sterigenics | Sale | 126,611 | $16.38 | $2.1M | Form 4 |
| Sep 6, 2024 | Warburg Pincus Private Equity XI-C, L.P.Director | Sale | 15,000,000 | $15.03 | $225.4M | Form 4 |
All 28 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Sachem Head Capital Management LPSCHEDULE 13G/A, 2 filings May 15, 2026 to Oct 9, 202637
- Sculptor Capital LPSCHEDULE 13G/A, 3 filings Sep 11, 2025 to Aug 14, 202638
- Sessa Capital IM, L.P.SCHEDULE 13G/A, 1 filing Aug 14, 202639
- BlackRockSCHEDULE 13G/A, 3 filings Oct 17, 2025 to Jul 30, 202640
- GTCR INVESTMENT XI LLCSCHEDULE 13G/A, 7 filings Feb 11, 2022 to May 15, 202641
- WARBURG PINCUS & CO.SCHEDULE 13G/A, 6 filings Feb 14, 2022 to May 15, 202642
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Nov 4, 2024 to Mar 27, 202643
- Sessa Capital (Master), L.P.SCHEDULE 13G, 1 filing Feb 17, 202644
- Darsana Capital Partners LPSCHEDULE 13G/A, 2 filings Sep 13, 2024 to Nov 14, 202545
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Sessa Capital IM, L.P. | 27,050,000 | $480.1M | 8.3% | +4,000,000 |
| Darsana Capital Partners LP | 27,000,000 | $479.2M | 2.2% | +1,000,000 |
| BlackRock, Inc. | 24,148,424 | $428.6M | 0.0% | +3,298,845 |
| Sculptor Capital LP | 24,000,000 | $426.0M | 6.1% | +2,282,272 |
| Sachem Head Capital Management LP | 15,560,000 | $276.2M | 5.7% | +3,915,000 |
| Vanguard Capital Management LLC | 12,170,699 | $216.0M | 0.0% | +1,435,693 |
| Vanguard Portfolio Management LLC | 11,946,341 | $212.0M | 0.0% | +1,337,624 |
| Aqr Capital Management LLC | 10,734,313 | $186.4M | 0.1% | +4,013,550 |
| Jupiter Topco LLC | 8,402,106 | $149.1M | 0.1% | New |
| State Street Corp | 8,324,321 | $147.8M | 0.0% | +1,302,695 |
| Fmr LLC | 6,173,320 | $109.6M | 0.0% | +6,144,727 |
| Two Seas Capital LP | 5,836,053 | $103.6M | 4.0% | −187,318 |
| Voss Capital, LP | 5,825,000 | $103.4M | 5.2% | +953,730 |
| Dimensional Fund Advisors LP | 5,799,870 | $102.9M | 0.0% | +280,995 |
| Geode Capital Management, LLC | 5,219,965 | $92.7M | 0.0% | +580,066 |
| Irenic Capital Management LP | 5,141,822 | $91.3M | 6.6% | +782,474 |
| DME Capital Management, LP | 4,135,515 | $73.4M | 1.9% | +2,069,835 |
| Lakewood Capital Management, LP | 3,979,581 | $70.6M | 3.7% | −125,000 |
| Norges Bank | 3,512,499 | $62.3M | 0.0% | New |
| ION Fund Management Ltd | 3,343,648 | $59.3M | 7.0% | +2,150,258 |
| Morgan Stanley | 3,075,334 | $54.6M | 0.0% | +1,012,853 |
| Charles Schwab Investment Management Inc | 2,803,452 | $49.8M | 0.0% | +310,179 |
| Dendur Capital LP | 2,770,000 | $49.2M | 2.9% | New |
| Ancora Advisors LLC | 2,683,637 | $47.6M | 0.9% | New |
| Gotham Asset Management, LLC | 2,206,457 | $39.2M | 0.1% | +1,059,576 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARMichael P. Rutz, President
- 15
- 16
- 17
- 18
- 19SEC EDGARTerry Hammons, SVP, GC and Secretary
- 20
- 21SEC EDGARRichard G. Kyle, Board member
- 22SEC EDGARKenneth D. Krause, Board member
- 23SEC EDGARHoldco L.p. Bull, Board member
- 24SEC EDGARChristopher Simon, Board member
- 25SEC EDGARKaren Flynn, Board member
- 26SEC EDGARRobert Brown Knauss, Board member
- 27SEC EDGARDavid E. Wheadon, Board member
- 28SEC EDGARAnn R. Klee, Board member
- 29SEC EDGARConstantine S. Mihas, Board member
- 30SEC EDGARDavid Donnini, Board member
- 31SEC EDGARJames Neary, Board member
- 32SEC EDGARRuoxi Chen, Board member
- 33
- 34SEC EDGARStephanie Geveda, Board member
- 35SEC EDGARVincent K. Petrella, Board member
- 36SEC EDGARAlexander Dimitrief, General counsel
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45